KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBIT (2016 - 2025)

Historic EBIT for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$31.7 million.

  • Nektar Therapeutics' EBIT rose 778.28% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 3591.34%. This contributed to the annual value of -$105.2 million for FY2024, which is 6010.45% up from last year.
  • Nektar Therapeutics' EBIT amounted to -$31.7 million in Q3 2025, which was up 778.28% from -$36.2 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' EBIT peaked at $14.3 million during Q4 2024, and registered a low of -$152.8 million during Q2 2022.
  • Moreover, its 5-year median value for EBIT was -$50.6 million (2023), whereas its average is -$68.6 million.
  • As far as peak fluctuations go, Nektar Therapeutics' EBIT plummeted by 4181.76% in 2021, and later surged by 14281.58% in 2024.
  • Quarter analysis of 5 years shows Nektar Therapeutics' EBIT stood at -$112.9 million in 2021, then surged by 53.53% to -$52.5 million in 2022, then surged by 36.13% to -$33.5 million in 2023, then soared by 142.82% to $14.3 million in 2024, then tumbled by 320.74% to -$31.7 million in 2025.
  • Its EBIT was -$31.7 million in Q3 2025, compared to -$36.2 million in Q2 2025 and -$44.5 million in Q1 2025.